Background Pain, fatigue and altered quality of life are frequent complaints in axial spondyloarthritis (axSpA), with an impact on disease activity evaluation, regardless radiographic or non-radiographic phenotype. No study compares face to the effects biologic DMARDs (bDMARDs) patient reported outcomes (PROs). Objectives To evaluate (bDMARDs: anti-TNF anti-IL17) three PROs (pain, fatigue, life...